Sublingual five-grass pollen tablets (Oralair®): A guide to their use as allergen immunotherapy for grass pollen-induced allergic rhinoconjunctivitis

Drugs and Therapy Perspectives

Volumn 30, Issue 6, 2014, Pages 200-208

  Lyseng Williamson, Katherine A ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

GRASS POLLEN EXTRACT; ORALAIR; UNCLASSIFIED DRUG;

CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; DRUG EFFICACY; DRUG INDICATION; DRUG TOLERABILITY; GRASS POLLEN; HUMAN; PRACTICE GUIDELINE; REVIEW; RHINOCONJUNCTIVITIS; SUBLINGUAL IMMUNOTHERAPY;

EID: 84902330394     PISSN: 11720360     EISSN: 11791977     Source Type: Journal    
DOI: 10.1007/s40267-014-0131-7     Document Type: Review

References (37)

1. Braido F, Arcadipane F, Marugo F, et al. Allergic rhinitis: current options and future perspectives. Curr Opin Allergy Clin Immunol. 2014;14(2):168-76.
2. Brożek JL, Bousquet J, Baena-Cagnani CE, et al. Allergic rhinitis and its impact on asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010;126(3):466-76.
3. Brehler R, Klimek L, Kopp MV, et al. Specific immunotherapy-indications and mode of action. Dtsch Arztebl Int. 2013;110(9):148-58.
4. Burks AW, Calderon MA, Casale T, et al. Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. J Allergy Clin Immunol. 2013;131(5):1288-96.
5. Zuberbier T, Bachert C, Bousquet PJ, et al. GA2LEN/EAACI pocket guide for allergen-specific immunotherapy for allergic rhinitis and asthma. Allergy. 2010;65(12):1525-30.
6. Canonica GW, Cox L, Pawankar R, et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J. 2014;7(1):6.
7. Fujita JH, Soyka MB, Akdis M, et al. Mechanisms of allergen-specific immunotherapy. Clin Transl Allergy. 2012;2(1):2. doi:10.1186/2045-7022-2-2.
8. Oralair® (sweet vernal, orchard, perennial rye, timothy, and Kentucky blue grass mixed pollen allergen extract) tablet for sublingual use: US prescribing information. Antony: Stallergenes S.A.; 2014.
9. Oralair® 100 and 300 IR sublingual tablets: summary of product characteristics. Antony: Stallergenes S.A.; 2013.
10. Didier A, Malling HJ, Worm M, et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol. 2007;120(6):1338-45. (Pubitemid 350225683)
11. Cox LS, Casale TB, Nayak AS, et al. Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: the importance of allergen-specific serum IgE. J Allergy Clin Immunol. 2012;130(6):1327-34.
12. Wahn U, Tabar A, Kuna P, et al. Efficacy and safety of 5-grasspollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2009;123(1):160-6.
13. Dider A, Worm M, Horak F, et al. Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis. J Allergy Clin Immunol. 2011;128(3):559-66.
14. Horak F, Zieglmayer P, Zieglmayer R, et al. Early onset of action of a 5-grass-pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber. J Allergy Clin Immunol. 2009;124(3):471-7.
15. Karagiannis E, Hadler M, Shah-Hosseini K, et al. Non-interventional 2-year-study of sublingual immunotherapy (SLIT) in patients with allergic rhinoconjunctivitis caused by grass pollen [abstract plus poster no. 1323]. In: European Academy of Allergy and Clinical Immunology-World Allergy Organization World Allergy and Asthma Congress; 22-26 June 2013; Milan.
16. Pastorello EA, Losappio L, Milani S, et al. 5-grass pollen tablets achieve disease control in patients with seasonal allergic rhinitis unresponsive to drugs: a real-life study. J Asthma Allergy. 2013;6:127-33.
17. Antolin D, Valbuena T, Valls A, et al. One season of treatment with 5 grass pollen tablets in adults demonstrated a reduction in disease symptoms and impacts: findings of the SMILE study [abstract plus poster no. 1315]. In: European Academy of Allergy and Clinical Immunology-World Allergy Organization World Allergy and Asthma Congress; 22-26 June 2013; Milan.
18. Didier A, Melac M, Montagut A, et al. Agreement of efficacy assessments for five-grass pollen sublingual tablet immunotherapy. Allergy. 2009;64(1):166-71.
19. Horak F, Jaeger S, Worm M, et al. Implementation of pre-seasonal sublingual immunotherapy with a five-grass pollen tablet during optimal dosage assessment. Clin Exp Allergy. 2009;39(3):394-400.
20. Malling H-J, Montagut A, Melac M, et al. Efficacy and safety of 5-grass pollen sublingual immunotherapy tablets in patients with different clinical profiles of allergic rhinoconjunctivitis. Clin Exp Allergy. 2009;39(3):387-93.
21. Halken S, Agertoft L, Seidenberg J, et al. Five-grass pollen 300IR SLIT tablets: efficacy and safety in children and adolescents. Pediatr Allergy Immunol. 2010;21(6):970-6.
22. Didier A, Malling H-J, Worm M, et al. Post-treatment efficacy of discontinuous treatment with 300IR 5-grass pollen sublingual tablet in adults with grass pollen-induced allergic rhinoconjunctivitis. Clin Exp Allergy. 2013;43(5):568-77.
23. Worm M, Didier A, Horak F, et al. Post-treatment, long-term efficacy of a 300 IR sublingual tablet of 5-grass pollen allergen extract in adults with grass pollen-induced allergic rhinoconjunctivitis: the relationship with disease severity [abstract no. 177]. J Allergy Clin Immunol. 2012;129(2):AB47
24. Oralair® sublingual tablets: Food and Drug Administration Allergenic Products Advisory Committee briefing document. Anthony: Stallergenes S.A.; 2013.
25. Grouin J-M, Vicaut E, Jean-Alphonse S, et al. The average Adjusted Symptom Score, a new primary efficacy end-point for specific allergen immunotherapy trials. Clin Exp Allergy. 2011;41(9):1282-8.
26. Canonica GW, Baena-Cagnani CE, Bousquet J, et al. Recommendations for standardization of clinical trials with allergen specific immunotherapy for respiratory allergy: a statement of a World Allergy Organization (WAO) taskforce. Allergy. 2007;62(3):317-24.
27. Devillier P, Le Gall M, Horak F. The allergen challenge chamber: a valuable tool for optimizing the clinical development of pollen immunotherapy. Allergy. 2011;66(2):163-9.
28. Karagiannis E, Hadler M, Shah-Hosseini K, et al. Full symptom control in patients with allergic rhinoconjuctivitis caused by grass pollen: results of a 2-year sublingual allergen immunotherapy (AIT) study [poster no. 1551]. In: European Academy of Allergy and Clinical Immunology-World Allergy Organization World Allergy and Asthma Congress; 22-26 June 2013; Milan.
29. Karagiannis E, Shah-Hosseini K, Hadler M, et al. PD14: non-interventional 2-year study of sublingual immunotherapy in children and adolescents with allergic rhinoconjunctivitis caused by grass pollen. Clin Transl Allergy. 2014;4(Suppl 1):P14.
30. Karagiannis E, Shah-Hosseini K, Hadler M, et al. P85: asthmatic children and adolescents treated in daily medical practice-results from a 2-year sublingual allergen immunotherapy (AIT) study with grass pollen tablets. Clin Transl Allergy. 2014;4(Suppl 1):P140.
31. Fernandez-Nieto M, Alvarez JA, Alvarado MI, et al. What is the opinion of the patients under 5 grass pollen tablets immunotherapy? First season assessment in adults: findings of the SMILE study [abstract plus poster no. 1328]. In: European Academy of Allergy and Clinical Immunology-World Allergy Organization World Allergy and Asthma Congress; 22-26 June 2013; Milan.
32. Iglesias-Cadarso A, Hernández-Weigand P. Risk factors for systemic reactions to allergen immunotherapy. Curr Opin Allergy Clin Immunol. 2011;11(6):579-85.
33. Radulovic S, Calderon M, Wilson D et al. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev. 2010;(12):CD002893.
34. Devillier P, Dreyfus J-F, Demoly P, et al. An evaluation of the relative clinical impact of sublingual allergen immunotherapy tablets and symptomatic medications in grass-pollen-induced allergic rhinoconjunctivitis [abstract no. 148]. In: European Academy of Allergy and Clinical Immunology-World Allergy Organization World Allergy and Asthma Congress; 22-26 June 2013; Milan.
35. Ruggeri M, Oradei M, Frati F, et al. Economic evaluation of 5-grass pollen tablets versus placebo in the treatment of allergic rhinitis in adults. Clin Drug Investig. 2013;33(5):343-9.
36. Westerhout KY, Verheggen BG, Schreder CH, et al. Cost effectiveness analysis of immunotherapy in patients with grass pollen allergic rhinoconjunctivitis in Germany. J Med Econ. 2012;15(5):906-17.
37. DranitsarisG,EllisAK. Sublingual or subcutaneous immunotherapy for seasonal allergic rhinitis: an indirect analysis of efficacy, safety and cost. J Eval Clin Pract. 2014. doi:10.1111/jep.12112.